(:LCI)

Business Focus: N/A

May 01, 2023 06:55 am ET

Lannett Company, Inc. Enters Into Restructuring Support Agreement

Restructuring Support Agreement Supported by Holders of More Than 80% of the Company's Senior Secured Notes and 100% of the Company's Second Lien Term Loans

Apr 20, 2023 06:53 am ET

NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

Company Expects No Impact on Operations

Apr 04, 2023 06:55 am ET

LANNETT SHARES UPDATE

Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product

Feb 01, 2023 03:15 pm ET

LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

Q2 Business and Financial Highlights:

Jan 25, 2023 03:30 pm ET

LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT

TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m. Eastern Time on February 6, 2023. Beginning February 7, 2023, the company's common stock will trade on a split-adjusted basis. The common stock will continue to trade on the New York Stock Exchange (NYSE) under the symbol "LCI," but will trade under the new CUSIP number 516012 200. The reverse stock split was approved by Lannett Company's stockholders at the co

Jan 25, 2023 05:52 am ET

LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1

TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance.

Jan 04, 2023 05:52 am ET

LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS

--Announces Positive Animal PK Study Results of Insulin Aspart Versus US NovoLog®--

Nov 07, 2022 05:52 am ET

LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM

TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin aspart development programs, that will provide a patent sublicense to the company and its strategic alliance partner within the HEC Group of companies (HEC).

Nov 02, 2022 04:15 pm ET

LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE

Q1 Business and Financial Highlights:

Oct 26, 2022 06:52 am ET

LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2

TREVOSE, Pa., Oct. 26, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance.

Oct 21, 2022 06:53 am ET

LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT

--Approval Allows Site to Rapidly Expand Liquid Drug Manufacturing--

Oct 19, 2022 06:55 am ET

LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS

-Companies Entered Into a Separate Private Label Agreement for Certain Other Lannett Generic Products-

Aug 31, 2022 06:53 am ET

LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE

No Reported Serious Adverse Events; Topline Results Expected Later This Year

Aug 24, 2022 04:15 pm ET

LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS

Q4 Business and Financial Highlights:

Aug 19, 2022 06:52 am ET

LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24

TREVOSE, Pa., Aug. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 fourth quarter and full year on Wednesday, August 24, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance.

Jun 01, 2022 06:52 am ET

LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE

Approximately Half of the Planned Number of Subjects Have Received the First Dose, With No Reported Serious Adverse Events

May 12, 2022 06:52 am ET

LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP

-- Current Drug Market Shortage Exists for Fludarabine Phosphate, An Injectable Chemotherapeutic Medication; Marketing Anticipated to Commence Later This Calendar Year --

May 04, 2022 04:15 pm ET

LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS

Q3 Business and Financial Highlights:

Apr 27, 2022 06:52 am ET

LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4

TREVOSE, Pa., April 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Mar 29, 2022 06:52 am ET

LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE

--First Patient Dosed, Topline Study Results Expected Later This Year; Potential BLA Filing in Early 2023 and Launch in the First Half of 2024--

Mar 18, 2022 04:15 pm ET

LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICE

TREVOSE, Pa., March 18, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 14, 2022, notifying the company that it is not in compliance with the continued listing standards set forth in Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's common stock was less than $1.00 per share over a consecutive 30 trading-day period.

Mar 04, 2022 04:33 pm ET

LANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14

TREVOSE, Pa., March 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company will participate in a fireside chat at the 34th Annual ROTH Conference on March 14, 2022 at 12:30 p.m. PT at The Ritz Carlton, in Laguna Niguel, California. The company expects to provide an update on its product development portfolio, including the status of its pending Abbreviated New Drug Application (ANDA) for generic Advair Diskus® - additional information below.

Mar 04, 2022 03:15 pm ET

LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE

TREVOSE, Pa., March 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 2, 2022, notifying the company that it is not in compliance with the continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual because its average market capitalization has been less than $50 million over a consecutive 30 trading-day period, and at the same time its last reported stockholders' equity was below $50 million.

Mar 04, 2022 05:52 am ET

LANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 million

PHILADELPHIA, March 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into material definitive agreements to sell its liquid drug manufacturing facility in Carmel, NY, as well as equipment located at the Carmel facility, certain Abbreviated New Drug Applications (ANDAs) and other assets to a private company for $10.5 million in cash, of which $9.0 million is due at closing. The transaction is anticipated to close within the next several weeks.

Feb 03, 2022 03:15 pm ET

LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE

TREVOSE, Pa., Feb. 3, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 second quarter ended December 31, 2021.

Jan 27, 2022 05:52 am ET

LANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3

TREVOSE, Pa., Jan. 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 second quarter on Thursday, February 3, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Jan 21, 2022 05:52 am ET

LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE

PHILADELPHIA, Jan. 21, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that they have completed the safety review of the Investigational New Drug (IND) application for biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC), and concluded that the company may proceed with the proposed clinical investigation. The company said it anticipates the pivotal clinical trial to commence by March 2022 and be completed

Dec 20, 2021 05:52 am ET

LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE

PHILADELPHIA, Dec. 20, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

Nov 03, 2021 04:15 pm ET

Lannett Reports Fiscal 2022 First-Quarter Financial Results; Revises Down Full-year Guidance

PHILADELPHIA, Nov. 3, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 first quarter ended September 30, 2021.

Oct 28, 2021 06:52 am ET

Lannett To Report Fiscal 2022 First-quarter Financial Results, Host Conference Call On Wednesday, November 3

PHILADELPHIA, Oct. 28, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 first quarter on Wednesday, November 3, 2021, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Aug 30, 2021 06:52 am ET

Lannett Commences Marketing Mycophenolate Mofetil For Oral Suspension

PHILADELPHIA, Aug. 30, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally developed product. Total U.S. sales of Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, according to IQVIA market, were approximately $68 million for the 12 months ending June 2021, although actual generic market values are expected to be lower.

Aug 25, 2021 04:15 pm ET

Lannett Announces Fiscal 2021 Fourth-Quarter, Full-Year Financial Results

PHILADELPHIA, Aug. 25, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 fourth quarter and full year ended June 30, 2021.

Aug 18, 2021 06:52 am ET

Lannett To Report Fiscal 2021 Fourth-quarter, Full-year Financial Results, Host Conference Call On Wednesday, August 25

PHILADELPHIA, Aug. 18, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 fourth quarter and full year on Wednesday, August 25, 2021, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Jul 29, 2021 06:52 am ET

LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler® (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd. The 10-year term of the agreement commences upon distribution of the product. U.S. sales of Spiriva Handihaler were $1.5 billion for the 12 months ending May, 2021 according to IQVIA, although actual generic market values are expected to be lower.

Jul 12, 2021 06:52 am ET

Lannett Launches Fluvastatin Sodium ER Tablets

PHILADELPHIA, July 12, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product. Total U.S. sales of Fluvastatin Sodium Extended-release Tablets, 80 mg, according to IQVIA market, were approximately $10 million for the 12 months ending May 2021, although actual generic market values are expected to be lower.

Feb 19, 2021 12:15 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company, Inc. - LCI

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Feb 09, 2021 05:53 am ET

Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin

PHILADELPHIA, Feb. 9, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of companies (HEC). Insulin aspart, a short-acting (fast-acting) insulin typically taken just before eating, is used to treat adults with Type 1 and Type 2 diabetes for the control of high blood sugar. Total U.S. sales for the 12 months ended December 2020 of various insulin asparts, including NovoLog®, exceeded $6.0 billion, according to IQVIA, although actual bios

Feb 08, 2021 05:52 am ET

Lannett Begins Marketing Chlorpromazine Hydrochloride Tablets

PHILADELPHIA, Feb. 8, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg. The company recently received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA). Total U.S. sales of the product, according to IQVIA market, were approximately $120 million for the 12 months ending November 2020, although actual generic market values are expected to be lower.

Feb 03, 2021 03:15 pm ET

Lannett Announces Fiscal 2021 Second-Quarter Financial Results In Line Or Above Expectations

PHILADELPHIA, Feb. 3, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 second quarter ended December 31, 2020.

Jan 27, 2021 05:52 am ET

Lannett To Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 3

PHILADELPHIA, Jan. 27, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 second quarter on Wednesday, February 3, 2021, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Dec 07, 2020 03:15 pm ET

Lannett Announces New $30 Million Revolving Credit Facility

PHILADELPHIA, Dec. 7, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the closing of a $30 million asset-backed revolving credit facility with Wells Fargo Bank, National Association.

Nov 30, 2020 05:52 am ET

Lannett Pays Off, In Full, Remaining Term A Loans

PHILADELPHIA, Nov. 30, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company used a portion of its existing cash on hand to pay off, in full, the remaining $42 million outstanding balance of its Term A Loans.

Nov 04, 2020 03:15 pm ET

Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance

PHILADELPHIA, Nov. 4, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 first quarter ended September 30, 2020.

Nov 03, 2020 05:52 am ET

Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules)

PHILADELPHIA, Nov. 3, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced the launch of the authorized generic of Tirosint® (Levothyroxine Sodium Capsules USP).

Oct 28, 2020 06:53 am ET

Lannett To Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call On Wednesday, November 4

PHILADELPHIA, Pa., Oct. 28, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 first quarter on Wednesday, November 4, 2020, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Aug 03, 2020 06:53 am ET

Lannett Announces Launch Of FDA Approved Levothyroxine Tablets

PHILADELPHIA, Aug. 3, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and distribution agreement.

Jul 27, 2020 06:52 am ET

Lannett To Launch Levorphanol Tablets

PHILADELPHIA, July 27, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will soon launch Levorphanol Tablets 2 mg, a partnered product.

Jul 23, 2020 06:52 am ET

Lannett Launches Mexiletine HCl Capsules

PHILADELPHIA, July 23, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the AB-rated generic equivalent to Mexitil® Capsules of Boehringer Ingelheim.

Jul 16, 2020 06:55 am ET

Lannett And Cediprof Announce Exclusive Distribution Agreement For An Approved Levothyroxine

PHILADELPHIA and CAGUAS, Puerto Rico, July 16, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) and Cediprof, Inc., a part of the Neolpharma Pharmaceutical Group family of companies, today said that the companies have entered into an interim exclusive supply and distribution agreement for Cediprof's FDA approved Levothyroxine Sodium Tablets USP. Lannett said it expects to commence distributing the product in the U.S. on August 3, 2020. The interim supply agreement terminates on July 31, 2022, when the previously announced 10-year exclusive supply and distribution agreement with Cedipro

Jul 13, 2020 06:52 am ET

Lannett Announces Restructuring, Cost Reduction Initiatives

PHILADELPHIA, July 13, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost savings plan. The initiatives include consolidating the research and development (R&D) function into a single location in Philadelphia and lowering operating costs. The company's workforce will be reduced by approximately 80 positions, equal to approximately 8.5% of the company's total number of employees. The company said that it expects these actions to result in cost savings in excess of $15 million annually.

Jun 11, 2020 06:52 am ET

Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting

PHILADELPHIA, June 11, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement program of its biosimilar insulin glargine partnered product candidate. Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar. Total U.S. sales of the glargine related products, according to IQVIA, were approximately $9.5 billion f

May 06, 2020 04:15 pm ET

Lannett Announces Fiscal 2020 Third-Quarter Financial Results

PHILADELPHIA, May 6, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 third quarter ended March 31, 2020.

Apr 29, 2020 06:52 am ET

Lannett To Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 6

PHILADELPHIA, April 29, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 third quarter on Wednesday, May 6, 2020, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Apr 08, 2020 06:52 am ET

Lannett To Meet With FDA Regarding The Clinical Advancement Of Biosimilar Insulin Glargine On June 9

PHILADELPHIA, April 8, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it is set to meet with the U.S. Food and Drug Administration (FDA) on June 9, 2020 to plan next steps for the clinical advancement of its biosimilar insulin glargine partnered product candidate. Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar.

Mar 31, 2020 06:54 am ET

Lannett Begins Marketing Generic Adderall® XR

PHILADELPHIA, March 31, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine capsule product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg capsules. Adderall XR® and its generic versions have an estimated IQVIA market value of approximately $1.3 billion for the 12 months ending January 2020, although actual generic market values ar

Nov 06, 2019 03:15 pm ET

Lannett Announces Fiscal 2020 First-Quarter Financial Results

PHILADELPHIA, Nov. 6, 2019 /PRNewswire/ --

Oct 30, 2019 06:52 am ET

Lannett To Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call On Wednesday, November 6

PHILADELPHIA, Oct. 30, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 first quarter on Wednesday, November 6, 2019, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Oct 04, 2019 10:00 pm ET

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Lannett Company, LogMeIn, and Mammoth Energy and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of Lannett Company, Inc. (NYSE: LCI), LogMeIn, Inc. (NASADQ: LOGM), and Mammoth Energy Services, Inc. (NASDAQ: TUSK) on behalf of long-term stockholders. More information about...

Oct 01, 2019 06:52 am ET

Lannett Enters Into Distribution Agreement For Generic ADVAIR DISKUS®

PHILADELPHIA, Oct. 1, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of ADVAIR DISKUS® (Fluticasone Propionate – Salmeterol Xinafoate Powder Inhaler) of Respirent Pharmaceuticals Co. Ltd. ADVAIR DISKUS had U.S. sales of $3.6 billion for the 12 months ending July, 2019, according to IQVIA, although actual generic market values are expected to be lower.

Sep 27, 2019 04:15 pm ET

Lannett Announces Closing Of $86.25 Million Of Convertible Senior Notes Due 2026

PHILADELPHIA, Sept. 27, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") today announced the closing of $86.25 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Lannett granted the initial purchaser of the Notes a 30-day option to purchase up to an additional $11.25 million aggregate principal amount of the Notes, which option the initial purchaser exercised in full.

Sep 25, 2019 07:40 am ET

Lannett Announces pricing of $75 million of Convertible Senior Notes Due 2026

PHILADELPHIA, Sept. 25, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") today announced the pricing of $75 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Lannett also granted the initial purchaser of the Notes a 30-day option to purchase up to an additional $11.25 million aggregate principal amount of the Notes. The sale of the Notes to the initial purchaser is expec

Sep 24, 2019 04:15 pm ET

Lannett Announces Offering of $75 million of Convertible Senior Notes Due 2026

PHILADELPHIA, Sept. 24, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it intends to offer, subject to market conditions and other factors, $75 million aggregate principal amount of convertible senior notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Lannett also intends to grant the initial purchaser of the Notes a 30-day option to purchase up to an additional $11.25 million aggregate principal amount of the Notes.

Aug 28, 2019 09:31 am ET

Thinking about buying stock in Aurora Cannabis, Lannett, Intec Pharma, Tilray, or Yelp?

NEW YORK, Aug. 28, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, LCI, NTEC, TLRY, and YELP.

Aug 28, 2019 06:52 am ET

Lannett Enters Into Distribution Agreement For Posaconazole Delayed-Release Tablets; Launch To Commence Shortly

PHILADELPHIA, Aug. 28, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Sinotherapeutics Inc., a China-based specialty pharmaceutical company, to be the exclusive U.S. distributor of Posaconazole Delayed-Release Tablets 100mg. Sinotherapeutics has received final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Posaconazole Delayed-Release Tablets 100mg, which is an AB-rated generic equivalent of Merck's Noxafil® Delayed-Release Tablets. Lannett expects to commence sh

Aug 27, 2019 04:15 pm ET

Lannett Announces Fiscal 2019 Fourth-Quarter, Full-Year Financial Results; Issues Guidance For Fiscal 2020

PHILADELPHIA, Aug. 27, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 fourth quarter and full year ended June 30, 2019.

Aug 27, 2019 06:52 am ET

Lannett Enters Into Advisory Services Agreement With Strategic Alliance Partner

PHILADELPHIA, Aug. 27, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a three-year advisory services agreement with its strategic alliance partner, Cediprof, Inc., a wholly owned subsidiary of privately held Neolpharma Group. This agreement is separate and in addition to the supply and distribution agreement for Levothyroxine Sodium Tablets USP recently entered into by the companies.

Aug 20, 2019 06:52 am ET

Lannett To Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call On Tuesday, August 27

PHILADELPHIA, Aug. 20, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 fourth quarter and full year on Tuesday, August 27, 2019, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Aug 14, 2019 09:02 pm ET

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Lannett, Molson Coors, AxoGen, and American Renal Associates and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of Lannett Company, Inc. (NYSE: LCI), Molson Coors Brewing Company (NYSE: TAP), AxoGen, Inc. (NASDAQ: AXGN), and American Renal Associates Holdings, Inc. (NYSE: ARA) on behalf of...

Aug 01, 2019 04:15 pm ET

Lannett Appoints John Kozlowski CFO

PHILADELPHIA, Aug. 1, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of John Kozlowski as chief financial officer (CFO), effective August 31, 2019. He succeeds Martin Galvan, who, as previously announced, will retire on August 30, 2019, following the planned submission of the company's Form 10-K for fiscal year 2019. Kozlowski presently serves as the company's chief of staff and strategy officer.

Jul 25, 2019 05:45 pm ET

Robbins Arroyo LLP: Shareholder Class Action Against Lannett Company (LCI) Survives Motion to Dismiss

Shareholder rights law firm Robbins Arroyo LLP announces that Lannett Company (NYSE: LCI) may face damages caused by a pending securities lawsuit. Lannett develops, manufactures, and distributes generic versions of brand pharmaceutical products in the United States.

Jul 08, 2019 06:52 am ET

Lannett Enters Into Distribution Agreement For Levothyroxine

PHILADELPHIA, July 8, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a future exclusive supply and distribution agreement for the approved Levothyroxine Sodium Tablets USP of Cediprof, Inc., a wholly owned subsidiary of privately held Neolpharma Pharmaceutical Group.

Jul 03, 2019 06:52 am ET

FDA Clears Path For The Continuing Review Of Lannett Company's New Drug Application

PHILADELPHIA, July 3, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today commented on the U.S. Food and Drug Administration's (FDA) denial of a Citizen Petition submitted by Genus Lifesciences requesting that the FDA refuse to accept any submissions related to Lannett's 505(b)(2) New Drug Application (NDA) for Cocaine Hydrochloride Topical Solution, 4% and 10%.

May 24, 2019 06:52 am ET

Lannett Announces CFO Retirement

PHILADELPHIA, May 24, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company's chief financial officer (CFO), Martin Galvan, 67, will retire on August 30, 2019, following the planned submission of the company's Form 10-K for fiscal year 2019. Galvan will continue in his role as CFO until then and thereafter serve as a consultant, as necessary.

May 23, 2019 04:08 pm ET

(LCI) Alert: Johnson Fistel, LLP Announces Investigation of Lannett Company, Inc.; Long Term Investors Encouraged to Contact Firm

SAN DIEGO, May 23, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Lannett Company, Inc. (NYSE: LCI) ("Lannett") and certain of its officers.

May 23, 2019 06:52 am ET

Lannett Appoints Melissa V. Rewolinski, PhD, To Board Of Directors

PHILADELPHIA, May 23, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 1, 2019. Following the appointment of Dr. Rewolinski, the board will comprise eight directors.

May 21, 2019 09:00 am ET

Haeggquist & Eck Investigates Conspiracy to Fix Prices on Generic Drugs by Lannett Officers and Directors

Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain officers and directors of

May 21, 2019 06:52 am ET

Lannett Purchases Additional $30.5 Million Of Term A Loans

PHILADELPHIA, May 21, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $30.5 million, face value, of its Term A Loans in a private transaction.

May 17, 2019 07:47 pm ET

Robbins Arroyo LLP: Shareholder Class Action Against Lannett Company (LCI) Survives Motion to Dismiss

Shareholder rights law firm Robbins Arroyo LLP announces that Lannett Company (NYSE: LCI) may face damages caused by a pending securities lawsuit action lawsuit. Lannett develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States.

May 16, 2019 07:42 pm ET

Bragar Eagel & Squire, P.C. is Investigating Lannett Company, Inc. (NYSE: LCI) on Behalf of Lannett Stockholders and Encourages Lannett Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Lannett Company, Inc. (NYSE: LCI) on behalf of Lannett stockholders. Our investigation concerns whether Lannett has violated the federal securities laws and/or engaged in other...

May 16, 2019 06:52 am ET

Lannett Begins Marketing Generic Adderall®

PHILADELPHIA, May 16, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing a generic version of Adderall®, an immediate-release (IR) mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg tablets. Adderall® including generic versions have an estimated IQVIA market value of approximately $349 million for the 12 months ending March 2019, although actual generic market values

May 13, 2019 05:49 pm ET

LANNETT INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lannett Company, Inc. To Contact The Firm

NEW YORK, May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lannett Company, Inc. ("Lannett" or the "Company") (NYSE:LCI).

May 07, 2019 04:17 pm ET

SHAREHOLDER ALERT: Investigation of Lannett Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether certain statements made by Lannett Company, Inc. (“Lannett” or the “Company”) (NYSE: LCI) complied with federal securities laws. On May 7, 2019, Lannett filed a Form 10-Q stating that on May 1, 2019 the Company and one of its employees received written notice from various state Attorneys General that they intend to bring claims alleging price fixing and anti-competitive behavior with respect to certain drug products, some of which are manufactured and distributed by the Company. The price of Lannett’

May 07, 2019 02:23 pm ET

Lannett Company Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, is investigating whether Lannett Company Inc. (“Lannett” or the “Company”) (NYSE: LCI) and certain of its officers and directors violated federal securities laws. On...

May 06, 2019 04:15 pm ET

Lannett Announces Fiscal 2019 Third-Quarter Financial Results; Raises Guidance For Fiscal 2019

PHILADELPHIA, May 6, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 third quarter ended March 31, 2019.

Apr 30, 2019 06:52 am ET

Lannett To Launch Generic Concerta®, AB-rated Methylphenidate Hydrochloride ER Tablets

PHILADELPHIA, April 30, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it expects to launch later this quarter Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths, an AB-rated generic equivalent to the brand Concerta®. Total U.S. sales of Methylphenidate Hydrochloride ER tablets were approximately $1.4 billion for the 12 months ended February 2019, according to IQVIA, although actual generic market values are expected to be lower.

Apr 29, 2019 06:52 am ET

Lannett To Report Fiscal 2019 Third-Quarter Financial Results, Host Conference Call On Monday, May 6

PHILADELPHIA, April 29, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 third quarter on Monday, May 6, 2019, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Apr 12, 2019 08:55 am ET

Detailed Research: Economic Perspectives on Global Brass and Copper, Lannett, NantHealth, Ballantyne Strong, Barnwell Industries, and Chicago Rivet & Machine — What Drives Growth in Today's Competitiv

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Global Brass and Copper Holdings, Inc. (NYSE:BRSS), Lannett Co Inc (NYSE:LCI),...

Mar 27, 2019 06:52 am ET

Lannett Receives FDA Approval For Aspirin And Extended-Release Dipyridamole Capsules, 25 mg/200 mg

PHILADELPHIA, March 27, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox® Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. Total U.S. sales of Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, was approximately $174.6 million for the 12 months ended January 2019, according to IQV

Mar 21, 2019 06:54 am ET

Lannett Purchases $24 Million Of Term Loans In Open Market Transactions

PHILADELPHIA, March 21, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $24.2 million principal amount of its Term Loans in open market transactions. The purchases comprised approximately $8.0 million and $16.2 million of the Term A Loans and Term B Loans, respectively.

Mar 11, 2019 06:45 am ET

Lannett Enters Into Distribution Agreement For Generic Adderall®

PHILADELPHIA, March 11, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of a generic version of Adderall®, an immediate-release mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg tablets. Adderall® is a central nervous system (CNS) stimulant, indicated for the treatment of

Feb 26, 2019 05:52 am ET

Lannett To Participate At Two Investor Conferences In March

PHILADELPHIA, Feb. 26, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below:

Feb 06, 2019 03:15 pm ET

Lannett Announces Record Net Sales In The Fiscal 2019 Second-Quarter Financial Results; Raises Guidance For Fiscal 2019

PHILADELPHIA, Feb. 6, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 second quarter ended December 31, 2018.

Jan 30, 2019 05:52 am ET

Lannett To Report Fiscal 2019 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 6

PHILADELPHIA, Jan. 30, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 second quarter on Wednesday, February 6, 2019, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Jan 22, 2019 05:52 am ET

Lannett Enters Into Distribution Agreement For Trientine Hydrochloride Capsules, Launch Imminent

PHILADELPHIA, Jan. 22, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with a strategic alliance partner to be the exclusive U.S. distributor of Trientine Hydrochloride Capsules, 250 mg, which is the AB-rated generic equivalent to Syprine® of Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.). Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a percentage of net profits. Other financial terms were not disclosed.

Dec 18, 2018 07:20 am ET

Recent Analysis Shows MTS, Columbia Sportswear, First Data, Boingo Wireless, Lannett, and Caterpillar Market Influences — Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MTS Systems Corporation (NASDAQ:MTSC), Columbia Sportswear Company...

Dec 11, 2018 05:52 am ET

Lannett Announces Amendment To Credit Agreement

PHILADELPHIA, Dec. 11, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an amendment of its credit agreement effecting the term A loans thereunder (Term A Loans) to provide the company greater flexibility with regard to its financial leverage ratio covenant applicable to such Term A Loans. With the amended leverage ratios, the company expects to be well within its financial covenants through the maturity date of the Term A Loans.

Dec 05, 2018 05:52 am ET

Lannett To Present At The BMO Capital Markets Prescription For Success Healthcare Conference On December 12

PHILADELPHIA, Dec. 5, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2018 Prescription for Success Healthcare Conference on December 12, 2018 at 2:40 p.m. (ET) at The Mandarin Oriental, New York hotel.

Nov 12, 2018 05:54 am ET

Lannett Enters Into Agreement With Amneal Pharmaceuticals For Levothyroxine

PHILADELPHIA, Nov. 12, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Amneal Pharmaceuticals, Inc. (Amneal) with regard to Levothyroxine Sodium Tablets USP. Under the agreement, Amneal will be Lannett's sole customer for Levothyroxine Sodium beginning December 1, 2018 through March 23, 2019, and will re-sell the products to its customers. Lannett will receive an upfront payment of $50 million, other terms of the transaction were not disclosed.

Nov 08, 2018 07:07 pm ET

Robbins Arroyo LLP: Lannett Company (LCI) Misled Shareholders According to a Shareholder Complaint

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Lannett Company (NYSE: LCI) have filed a shareholder complaint against the company's officers and directors for breaches of fiduciary duty from 2013 to the present for their role in allegedly causing Lannett to engage in a pric

Nov 07, 2018 03:15 pm ET

Lannett Announces Fiscal 2019 First-Quarter Financial Results; Re-Affirms Adjusted Guidance For Fiscal 2019

PHILADELPHIA, Nov. 7, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 first quarter ended September 30, 2018.

Nov 06, 2018 05:54 am ET

Lannett Announces Expanded Agreement With Strategic Alliance Partner, HEC Pharm Group, To Distribute Two FDA-Approved Products

PHILADELPHIA, Nov. 6, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has expanded its agreement with Sunshine Lake LLC, the U.S. subsidiary of the HEC Pharm Group (HEC) of China, to be the exclusive distributor in the U.S. of Clarithromycin Extended Release (ER) Tablets 500 mg and Entacapone Immediate Release (IR) Tablets 200 mg. HEC has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Clarithromycin Extended Release (ER) Tablets 500 mg and Entacapone Immediate Release (IR) Tablets 200 mg,

Nov 05, 2018 08:20 am ET

Investor Expectations to Drive Momentum within Radian Group, Microvision, Lannett, American Outdoor Brands, Mondelez International, and Ambarella — Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Radian Group Inc. (NYSE:RDN), Microvision, Inc. (NASDAQ:MVIS), Lannett...

Nov 01, 2018 06:46 am ET

Lannett Enters Into Distribution Agreement For Vardenafil Hydrochloride Tablets

PHILADELPHIA, Nov. 1, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Rivopharm SA to be the exclusive U.S. distributor of Vardenafil Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, which is the AB-rated generic equivalent to Levitra® of Bayer Healthcare Pharmaceuticals Inc. Vardenafil Hydrochloride Tablets are indicated for the treatment of erectile dysfunction.

Nov 01, 2018 06:31 am ET

Lannett To Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call On Wednesday, November 7

PHILADELPHIA, Nov. 1, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 first quarter on Wednesday, November 7, 2018, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.

Oct 26, 2018 02:05 pm ET

SHAREHOLDER ALERT: LCI CBS QRTEA USAT COCP ALNY CHGG JT DY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Oct 25, 2018 04:28 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, TGTX and SFIX

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Oct 25, 2018 03:21 pm ET

FRIDAY DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Lannett Company, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE:

Oct 24, 2018 07:00 pm ET

Rosen Law Firm Reminds Lannett Company, Inc. Investors of Important October 26 Deadline in Class Action

NEW YORK, Oct. 24, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Lannett Company, Inc. (NYSE: LCI) from February 7, 2018 through August 17, 2018, inclusive (the "Class Period") of the important October 26, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Lannett investors under the federal securities laws.

Oct 24, 2018 04:00 pm ET

CLASS ACTION UPDATE for LCI, MGTI, HAS and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...

Oct 24, 2018 02:49 pm ET

FRIDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Lannett Company, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) for violations of §§10(b) and 20(a) of the Securities Exchange...

Oct 24, 2018 08:41 am ET

KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for LANNETT COMPANY, INC. Investors – LCI

Kessler Topaz Meltzer Check, LLP reminds Lannett Company, Inc. (NYSE: LCI) (“Lannett”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf...

Oct 23, 2018 03:55 pm ET

SHAREHOLDER ALERT: AMPE LCI PZZA SKX PM USAT COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Oct 23, 2018 02:30 pm ET

3-DAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lannett Company, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE:

Oct 22, 2018 05:22 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, PZZA, ALNY, SFIX and GOOG

Oct 22, 2018 01:16 pm ET

FINAL DEADLINE ALERT: Kaskela Law LLC Files Investor Class Action Against Lannett Company, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Before Deadline

Kaskela Law LLC has filed an investor class action lawsuit against Lannett Company, Inc. (NYSE: LCI) (“Lannett” or the “Company”) on behalf of purchasers of the Company’s securities between February 7, 2018 and August 17, 2018, inclusive (the...

Oct 22, 2018 11:59 am ET

CLASS ACTION UPDATE for LCI, TRVN and GOOG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Oct 22, 2018 10:00 am ET

SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lannett Company, Inc. (LCI) and Lead Plaintiff Deadline – October 26, 2018

Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC notifies investors that a class action lawsuit has been filed against Lannett Company, Inc. (“Lannett” or the “Company”) (NYSE: LCI) and certain of its officers, on behalf of shareholders...

Oct 22, 2018 09:23 am ET

Kessler Topaz Meltzer & Check, LLP – Important Deadline Reminder for Lannett Company, Inc. Investors

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Lannett Company, Inc. (NYSE: LCI) (“Lannett”) investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of Lannett securities between February 7, 2018 and August 17, 2018, inclusive (the “Class Period”).

Oct 22, 2018 06:52 am ET

Lannett And Adare Enter Into Distribution Agreement For Dexmethylphenidate Hydrochloride Extended Release Capsules

PHILADELPHIA and PRINCETON, N.J., Oct. 22, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Adare Pharmaceuticals, Inc., to be the exclusive U.S. distributor of Dexmethylphenidate Hydrochloride Extended Release (ER) Capsules USP (CII), 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg. Lannett expects to commence marketing within a few months.

Oct 21, 2018 11:08 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, PVG, ALNY, MGTI, HAS and CHGG

Oct 19, 2018 06:28 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline – LCI

Pomerantz LLP announces that a class action lawsuit has been filed against Lannett Company, Inc. (“Lannett” or the “Company”) (NYSE: LCI) and certain of its officers. The class action, filed in United States District Court, Eastern District of...

Oct 19, 2018 12:47 pm ET

CLASS ACTION UPDATE for LCI, OPK, MCHP and CPB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Oct 17, 2018 03:07 pm ET

SHAREHOLDER ALERT: PDD AMPE NVRO LCI CBS PZZA OPK QRTEA PVG COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Oct 17, 2018 12:00 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO, LCI, LOGM and HTHT

Oct 16, 2018 07:46 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ampio, Lannett, and Papa John’s and Encourages Investors to Contact the Firm

Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Ampio Pharmaceuticals, Inc., Lannett Company, Inc., and Papa John’s International, Inc. Stockholders have until the deadlines...

Oct 16, 2018 03:15 pm ET

Kaskela Law LLC Files Shareholder Class Action Lawsuit Against Lannett Company, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Before Important Deadline - LCI

Kaskela Law LLC has filed a shareholder class action lawsuit against Lannett Company, Inc. (NYSE: LCI) (“Lannett” or the “Company”) on behalf of purchasers of the Company’s securities between February 7, 2018 and August 17, 2018, inclusive (the...

Oct 16, 2018 12:44 pm ET

Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Lannett Investors

The law firm of Kessler Topaz Meltzer Check, LLP reminds Lannett Company, Inc. (NYSE: LCI) (“Lannett”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of...

Oct 16, 2018 11:45 am ET

CLASS ACTION UPDATE for AMPE, NVRO and LCI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Oct 16, 2018 10:00 am ET

SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lannett Company, Inc. (LCI) and Lead Plaintiff Deadline – October 26, 2018

Oct 14, 2018 10:09 am ET

SHAREHOLDER ALERT: NVRO LCI CBS PZZA LOGM SKX OPK PM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Oct 13, 2018 01:00 pm ET

LCI LOSS ALERT: Rosen Law Firm Reminds Lannett Company, Inc. Investors of Important Deadline in Class Action – LCI

Oct 12, 2018 07:05 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline – LCI

Oct 11, 2018 01:31 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, CBS, LOGM, SKX and QRTEA

Oct 10, 2018 07:19 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CV Sciences, Lannett, and Ampio and Encourages Investors to Contact the Firm

Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of CV Sciences, Inc., Lannett Company, Inc., and Ampio Pharmaceuticals, Inc. Stockholders have until the deadlines listed below...

Oct 10, 2018 02:59 pm ET

SHAREHOLDER ALERT: LCI CBS PZZA LOGM QRTEA PVG TGTX HAS CPB ACHC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Oct 10, 2018 01:00 pm ET

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lannett Company, Inc. (LCI) and Lead Plaintiff Deadline – October 26, 2018

Oct 10, 2018 10:54 am ET

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Lannett Company, Inc. – LCI

Oct 10, 2018 08:20 am ET

Consolidated Research: 2018 Summary Expectations for Macerich, Deluxe, RadiSys, Lannett, Ambarella, and Phibro Animal Health — Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Macerich Company (NYSE:MAC), Deluxe Corporation (NYSE:DLX), RadiSys...

Oct 09, 2018 10:29 am ET

CLASS ACTION UPDATE for LCI and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Oct 08, 2018 04:42 pm ET

INVESTOR ALERT: Kaskela Law LLC Files Investor Class Action Lawsuit Against Lannett Company, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Oct 08, 2018 09:31 am ET

Lannett Engages Advisors To Explore And Evaluate Debt And Capital Structure Alternatives

PHILADELPHIA, Oct. 8, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has engaged and/or expanded the role of existing advisors to assist in evaluating a range of alternatives regarding the company's debt and capital structure.

Oct 07, 2018 11:00 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PDD, LCI, PZZA, LOGM, PM and QRTEA

Oct 05, 2018 05:19 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline – LCI

Oct 05, 2018 11:50 am ET

SHAREHOLDER ALERT: PDD AMPE NVRO LCI CBS PZZA LOGM SKX PM QRTEA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Oct 03, 2018 06:56 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nevro, CV Sciences, and Lannett and Encourages Investors to Contact the Firm

Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nevro Corp., CV Sciences, Inc., and Lannett Company, Inc. Stockholders have until the deadlines listed below to petition the...

Oct 03, 2018 03:11 pm ET

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Lannett Company, Inc.

The law firm of Kessler Topaz Meltzer Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in United States District Court for the Eastern District of Pennsylvania on behalf of purchasers of Lannett Company,...

Oct 03, 2018 10:00 am ET

SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lannett Company, Inc. (LCI) and Lead Plaintiff Deadline – October 26, 2018

Oct 01, 2018 06:52 am ET

Lannett Launches Five New Products In Fiscal 2019 First Quarter

PHILADELPHIA, Oct. 1, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it commenced marketing five new products in its recently completed fiscal 2019 first quarter, bringing to 12 the total number of products launched since January 1, 2018.

Sep 30, 2018 11:14 am ET

CLASS ACTION UPDATE for LCI, PM and QRTEA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 28, 2018 02:41 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline – LCI

Sep 28, 2018 01:44 pm ET

SHAREHOLDER ALERT: AMPE LCI CBS PM SKX PVG OPK USAT TRCO COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Sep 28, 2018 10:29 am ET

LCI EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Lannett Company, Inc. – LCI

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Lannett Company, Inc. (NYSE: LCI) from February 7, 2018 through August 17, 2018, inclusive (the “Class...

Sep 27, 2018 04:02 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PDD, LCI, LOGM, PM, QRTEA, TRCO and ABBV

Sep 27, 2018 12:55 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVRO, LCI, PZZA, PM, and PVG

Sep 26, 2018 11:58 am ET

CLASS ACTION UPDATE for LCI, ORCL and LOGM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 26, 2018 10:00 am ET

SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lannett Company, Inc. (LCI) and Lead Plaintiff Deadline – October 26, 2018

Sep 25, 2018 09:37 am ET

Kessler Topaz Meltzer & Check, LLP Reminds Lannett Company, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit

Sep 23, 2018 10:00 am ET

SHAREHOLDER ALERT: TSLA PDD AMPE LCI CBS ORCL SBGI SKX PM QRTEA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Sep 21, 2018 06:00 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline – LCI

Sep 20, 2018 05:31 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO, LCI, CBS, PZZA, SKX, CRON, PM and QRTEA

Sep 20, 2018 12:39 pm ET

Hagens Berman Reminds Investors in Lannett Company, Inc. (NYSE: LCI) of the October 26, 2018 Securities Class Action Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP reminds investors in Lannett Company, Inc. (NYSE: LCI) of the October 26, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired Lannett Company securities...

Sep 20, 2018 10:00 am ET

SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lannett Company, Inc. (LCI) and Lead Plaintiff Deadline – October 26, 2018

Sep 19, 2018 09:19 am ET

Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Lannett Company, Inc. Investors

Sep 18, 2018 08:06 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lannett, Skechers, and USA Technologies and Encourages Investors to Contact the Firm

Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Lannett Company, Inc., Skechers U.S.A., Inc., and USA Technologies, Inc. Stockholders have until the deadlines listed below...

Sep 18, 2018 12:00 am ET

CLASS ACTION UPDATE for PDD, LCI and ORCL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 17, 2018 01:00 pm ET

SHAREHOLDER ALERT: TSLA PDD LCI CBS ORCL SBGI HMNY PVG OPK USAT TRCO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Sep 16, 2018 02:00 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, CBS and FB

Sep 14, 2018 07:29 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline – LCI

Sep 14, 2018 04:30 pm ET

SHAREHOLDER ALERT: AMPE NVRO LCI CBS PZZA FIZZ CRON PM QRTEA OPK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Sep 14, 2018 03:15 pm ET

CLASS ACTION UPDATE for LCI and CBS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 13, 2018 07:57 pm ET

LCI LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Lannett Company, Inc. - LCI

NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Lannett Company, Inc. (NYSE: LCI) from February 7, 2018 through August 17, 2018, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Lannett investors under the federal securities laws.

Sep 13, 2018 04:28 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, ACAD and FB

Sep 13, 2018 02:24 pm ET

Robbins Arroyo LLP: Lannett Company (LCI) Misled Shareholders According to a Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Lannett Company (NYSE: LCI) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between February 7, 2018 and August 17, 2018. Lannett d

Sep 13, 2018 12:28 pm ET

SHAREHOLDER ALERT: TSLA LCI CBS ORCL LOGM NLSN ZN RMTI HMNY SKX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Sep 12, 2018 05:46 pm ET

Lifshitz & Miller LLP Announces Investigation of American Express Company, GDS Holdings Limited, Lannett Company, Inc., Mednax, Inc., Menlo Therapeutics Inc., Papa John's International, Inc., Tetrapha

NEW YORK, Sept. 12, 2018 /PRNewswire/ --

Sep 12, 2018 02:26 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PDD, AMPE, LCI, CBS and PZZA

Sep 11, 2018 09:20 am ET

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Lannett Company, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Lannett Company, Inc. (NYSE: LCI) (“Lannett”) on behalf of purchasers of Lannett securities between February 7, 2018 and August 17, 2018, inclusive (the “Class Period”).

Sep 09, 2018 02:15 pm ET

CLASS ACTION UPDATE for TSLA, LCI and LOGM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 07, 2018 07:13 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline – LCI

Sep 06, 2018 01:00 pm ET

SHAREHOLDER ALERT: NVRO LCI CBS ORCL PZZA MRCY FIZZ HMNY SKX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Sep 06, 2018 08:34 am ET

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Lannett Company, Inc. - LCI

RADNOR, Pa., Sept. 6, 2018 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Lannett Company, Inc. (NYSE: LCI) ("Lannett") on behalf of purchasers of Lannett securities between February 7, 2018 and August 17, 2018, inclusive (the "Class Period").

Sep 05, 2018 05:28 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, PZZA, SKX and CRON

Sep 05, 2018 04:49 pm ET

KESSLER TOPAZ MELTZER & CHECK, LLP – Announces Investor Securities Fraud Class Action Lawsuit Against LANNETT COMPANY, INC. – LCI

The law firm of Kessler Topaz Meltzer Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Lannett Company, Inc. (NYSE: LCI)...

Sep 05, 2018 12:43 pm ET

CLASS ACTION UPDATE for AMPE, LCI and ZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 02, 2018 01:00 pm ET

SHAREHOLDER ALERT: GLNCY FB HMNY GDS NLSN LOGM AMPE NVRO LCI CBS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Sep 01, 2018 01:00 pm ET

LCI SHAREHOLDER NOTICE: Rosen Law Firm Reminds Lannett Company, Inc. Investors of Important Deadline in Class Action – LCI

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Lannett Company, Inc. (NYSE: LCI) from February 7, 2018 through August 17, 2018, inclusive (the “Class Period”) of the important October 26, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Lannett investors under the federal securities laws.

Aug 31, 2018 05:51 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline - LCI

NEW YORK, Aug. 31, 2018 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) and certain of its officers. The class action, filed in United States District Court, Eastern District of Pennsylvania, and docketed under 18-cv-3635, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Lannett securities between February 7, 2018 through August 17, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' viol

Aug 31, 2018 05:51 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline - LCI

NEW YORK, Aug. 31, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) and certain of its officers. The class action, filed in United States District Court, Eastern District of Pennsylvania, and docketed under 18-cv-3635, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Lannett securities between February 7, 2018 through August 17, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendant

Aug 31, 2018 02:24 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LOGM, AMPE, LCI, CBS and PZZA

Aug 31, 2018 11:25 am ET

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. (LCI) and Encourages Investors to Contact the Firm

Bragar Eagel Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired Lannett Company, Inc....

Aug 31, 2018 10:51 am ET

CLASS ACTION UPDATE for LCI and CBS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Aug 31, 2018 10:00 am ET

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Lannett Company, Inc. (LCI) and Lead Plaintiff Deadline – October 26, 2018

Aug 30, 2018 05:06 pm ET

SHAREHOLDER ALERT: GLNCY GLCNF ACAD GDS NLSN LOGM PDD NVRO LCI CBS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Aug 30, 2018 04:01 pm ET

INVESTOR ALERT: Kaskela Law LLC Files Shareholder Class Action Lawsuit Against Lannett Company, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Aug 30, 2018 01:19 pm ET

LANNETT COMPANY, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern Dist

Wolf Haldenstein Adler Freeman Herz LLP announces that a federal securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Lannett Company, Inc. (“Lannett” or the...

Aug 29, 2018 05:03 pm ET

CLASS ACTION UPDATE for TSLA and LCI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Aug 29, 2018 01:44 pm ET

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Lannett Company, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Lannett Company, Inc. ("Lannett" or the "Company") (NYSE:

Aug 29, 2018 01:32 pm ET

Hagens Berman Alerts Investors in Lannett Company, Inc. (NYSE: LCI) to the October 26, 2018 Securities Class Action Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP alerts investors in Lannett Company, Inc. (NYSE: LCI) to the October 26, 2018 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the Eastern District of...

Aug 28, 2018 04:15 pm ET

Lannett Announces Fiscal 2018 Fourth-Quarter And Full-Year Financial Results; Provides Guidance For Fiscal 2019

PHILADELPHIA, Aug. 28, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 fourth quarter and full year ended June 30, 2018.

Aug 28, 2018 12:42 pm ET

You are here

(:LCI)

Business Focus: N/A